Optimer Pharmaceuticals (Nasdaq: OPTR ) is expected to report Q4 earnings on Feb. 28. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Optimer Pharmaceuticals's revenues will drop -72.0% and EPS will shrink to a loss.
The average estimate for revenue is $18.1 million. On the bottom line, the average EPS estimate is -$0.51.
Last quarter, Optimer Pharmaceuticals recorded revenue of $17.9 million. GAAP reported sales were 62% higher than the prior-year quarter's $11.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.56. GAAP EPS were -$0.56 for Q3 versus -$0.57 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 25.3%, 2,500 basis points better than the prior-year quarter. Operating margin was -147.0%, 9,650 basis points better than the prior-year quarter. Net margin was -149.8%, 8,930 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $100.0 million. The average EPS estimate is -$1.19.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 107 members out of 144 rating the stock outperform, and 37 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Optimer Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $19.13.
- Add Optimer Pharmaceuticals to My Watchlist.